Vimarsana
Biggest News Aggregation in the World

Page 3 - Impacts Questionnaire News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Impacts Questionnaire. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Impacts Questionnaire Today - Breaking & Trending Today

SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia - Vimarsana News

SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia

Poster presentation of Wake Up America: The Night & Day Impact of Insomnia, the largest U.S. survey of people with trouble sleeping and doctors, to discover...

Europe's first dual orexin receptor antagonist – QUVIVIQ - Vimarsana News

Europe's first dual orexin receptor antagonist – QUVIVIQ

QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable...

Idorsia Pharmaceuticals Ltd: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder - Vimarsana News

Idorsia Pharmaceuticals Ltd: Europe's first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

QUVIVIQ? is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningComprehensive nighttime

Idorsia Pharmaceuticals Ltd: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - Vimarsana News

Idorsia Pharmaceuticals Ltd: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy

Allschwil, Switzerland - March 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that new data for daridorexant in patients with insomnia disorder, including long-term safety and efficacy data, will

Idorsia Pharmaceuticals Ltd: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder - Vimarsana News

Idorsia Pharmaceuticals Ltd: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for QUVIVIQ (daridorexant) for the treatment of adult patients